YTS109 cell
Phase 1Small molecule
YTS109 cell is one of 94 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.
3
Indications
10
Total Trials
9
Active Trials
93
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
328 competitors in Systemic Lupus Erythematosus
#DrugCompanyPhaseTrials
1Olumiant
Eli LillyPhase 3
Stelara
Johnson & JohnsonPhase 3
Rinvoq
AbbViePhase 3
Gazyva
RochePhase 3
Intrarosa
Alnylam PharmaceuticalsPhase 3
Rayos
RRoxane Laboratories
Phase 3
Cellcept
NovartisPhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Tylenol
KKenvue Brands
Phase 3
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Autoimmune Disease6 trials
Show 3 more trials
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
Not yet recruiting·—·Phase 1·NCT07439029·12 enrolled
Hemolytic Anemia3 trials
A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT07287930·13 enrolled
Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia
Not yet recruiting·CChina Immunotech (Beijing) Biotechnology Co., Ltd.·Phase 1·NCT07453836·13 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YTS109 cell. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details